Academic Pathophysiology, Pharmacology, and Physical Assessment (3Ps) Assessment Practice Exam

Parkinson's disease primarily affects movement through the dysfunction of dopaminergic pathways in the basal ganglia. The basal ganglia are a group of structures in the brain that are crucial for coordinating movement and ensuring smooth, purposeful motion. In Parkinson's disease, there is a progressive degeneration of dopamine-producing neurons in a specific part of the basal ganglia called the substantia nigra.

Dopamine is a key neurotransmitter that facilitates communication within the basal ganglia circuitry, which is essential for regulating voluntary movement. The loss of these dopaminergic neurons leads to an imbalance between excitatory and inhibitory signals in the motor pathways, resulting in the classic symptoms of Parkinson's disease, such as bradykinesia (slowed movement), rigidity, tremors, and postural instability.

The other options do not accurately reflect the mechanism of action in Parkinson's disease. For instance, increasing dopamine levels or enhancing muscle contraction might seem beneficial for movement, but they do not address the fundamental issue of dopamine depletion in the brain's circuitry. Blocking acetylcholine receptors is relevant in the context of other movement disorders but is not the primary mechanism in Parkinson's disease. Thus, focusing on how dopaminergic pathways are affected provides a clear understanding of how this